Alpha BreakingAAT: Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026
Friday, October 23, 2026 at 12:02 PM ET
Share this article
Spread the word on social media
Latest Updates
Oct 23, 3:00 PM
Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026
– CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z-A1AT in cellular assays and in the PiZ mouse model – MONTREAL, Oct. 23, 2026 /PRNewswire/ -- Congruence Therapeutics ("Congruence"), a clinical-stage, computationally driven biotechnology company building a pipeline...
Source: PR Newswire
Oct 23, 3:00 PM
Congruence Therapeutics Announces Oral Presentation on CGX-195, a Novel Small Molecule AAT Corrector, at the ERS Alpha-1 Antitrypsin (AAT) Conference 2026
– CGX-195 increased functional, secreted Z-A1AT and reduced polymerized Z-A1AT in cellular assays and in the PiZ mouse model – MONTREAL, Oct. 23, 2026 /PRNewswire/ -- Congruence Therapeutics ("Congruence"), a clinical-stage, computationally driven biotechnology company building a pipeline...
Source: PR Newswire